ArticleNature2023
PI3Kβ controls immune evasion in PTEN-deficient breast tumours.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
21.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).Nature communications · 2025Trial
- Integrated multi-omics analysis reveals the molecular landscape and therapeutic strategies in Chinese cervical cancer patients.PLoS biology · 2026Article
- PI3K/AKT signaling pathway: molecular crossroads in tumorigenesis and therapeutic innovation.Signal transduction and targeted therapy · 2026Review
- Engineered bacteria as exogenous organelle mimics restore PTEN and p53 tumor suppressor functions for cancer therapy.Nature communications · 2026Article
- HLA Class I Expression Is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.Molecular cancer research : MCR · 2026Article
- Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma.Cell reports. Medicine · 2026Article
- Sphingosine kinase-2 inhibition promotes immunogenic differentiation of myeloid-derived suppressor cells through an Acetyl-CoA carboxylase-phosphatidylcholine axis.Nature communications · 2026Article
- Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026Review
- A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026Review
- Loss of the tumor suppressor PTEN activates cell-intrinsic interferon signaling to drive immune resistance.Genes & development · 2026Article
- S-equol promotes ferroptosis in triple negative breast cancer by coordinating NCOA4-mediated ferritinophagy and PPARγ-mediated lipid metabolism.Molecular and cellular biochemistry · 2026Article
- PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis.Cancer discovery · 2026Article
- Chromatin regulatorsChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Schwann cell-derived extracellular vesicles inhibit osteoclastogenesis through the PTEN/AKT axis in peripheral nerve-bone crosstalk.Journal of nanobiotechnology · 2026Article
- The Roles of MicroRNAs, Oncogenes, and Tumor Suppressor Gene Molecular Subtypes of Breast Cancer: Therapeutic Potential of Pharmaceutical and Natural Products.International journal of breast cancer · 2026Review
- The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Review
- Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy.Frontiers in oncology · 2026Review
- STAT3 at the tumor-immune interface: mechanisms of immune escape and therapeutic opportunities.Frontiers in immunology · 2026Review
- Nanomaterial-based strategies overcome PD-1 related intrinsic immune resistance.Cancer drug resistance (Alhambra, Calif.) · 2026Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors at 5 institutions in 2 countries.
Johann S Bergholz *Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4609-8448
Qiwei Wang *Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3897-2529
Qi Wang *Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Michelle RamseierBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Sanjay PrakadanBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Weihua WangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rong FangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sheheryar KabrajiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5315-7103
Qian ZhouCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
G Kenneth GrayDepartment of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.
Kayley Abell-HartDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shaozhen XieDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Xiaocan GuoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hao GuDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Thanh VonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tao JiangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shuang TangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7210-5616
Hye-Jung KimDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5595-4264
Alex K ShalekBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5670-8778
Thomas M RobertsDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. thomas_roberts@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-6453-3955
Jean J ZhaoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. jean_zhao@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-4561-5688
Broad Institute · USHarvard University · USDana-Farber Cancer Institute · USFudan University Shanghai Cancer Center · CNUniversity of Nottingham Ningbo China · CN
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MTissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI MYLES A BROWN · 2013 to 2026
$30.1MIntegrating targeted therapy and immunotherapy to break through cancerR35CA210057 · NCI · DANA-FARBER CANCER INST · PI Jean Zhao · 2016 to 2026
$10.8MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6MQuantitative and functional characterization of therapeutic resistance in cancerU54CA217377 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WEINSTOCK, DAVID MARC · 2017 to 2021
$10.2MMaximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null CancersR35CA231945 · NCI · DANA-FARBER CANCER INST · PI ROBERTS, THOMAS M · 2019 to 2025
$7.1MCancer Chemical Biology and Metabolism Training ProgramT32CA236754 · NCI · DANA-FARBER CANCER INST · PI Nika N Danial, THOMAS M ROBERTS · 2019 to 2026
$2.6M"Bottom - Up" Profiling of Interacting Cellular SystemsDP2GM119419 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SHALEK, ALEX K · 2015 to 2015
$2.3MNCI NIH HHS P50 CA101942NCI NIH HHS P50 CA168504NCI NIH HHS P50 CA206963NCI NIH HHS R35 CA210057NCI NIH HHS R35 CA231945NCI NIH HHS T32 CA236754NCI NIH HHS U54 CA217377NIGMS NIH HHS DP2 GM119419
Abstract
Loss of the PTEN tumour suppressor is one of the most common oncogenic drivers across all cancer types
Indexed as
Immune EvasionMammary Neoplasms, AnimalPhosphatidylinositol 3-KinasePTEN PhosphohydrolaseAnimalsImmunotherapyMammary Neoplasms, ExperimentalMicePhosphoinositide-3 Kinase InhibitorsSignal TransductionTumor Suppressor Protein p53Phosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsPTEN PhosphohydrolasePten protein, mouseTrp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.